TABLE 5.

Effect of individual statins on primary and secondary outcomes in subjects with IBD.

Statin type	n(%)	Steroid use	Anti-TNF	Abdominal surgery	Hospitalization	Composite outcome
		HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Atorvastatin	639 (32.2)	0.76 (0.60, 0.96)	0.72 (0.35, 1.46)	0.71 (0.47, 1.07)	0.92 (0.70, 1.21)	0.81 (0.67, 0.99)
Fluvastatin	14 (0.7)	0.67 (0.09, 4.74)	NE	NE	1.18 (0.17, 8.40)	0.50 (0.07, 3.53)
Lovastatin	146 (7.4)	0.92 (0.58, 1.47)	NE	0.55 (0.21, 1.48)	0.82 (0.45, 1.49)	0.90 (0.61, 1.31)
Pravastatin	132 (6.7)	0.68 (0.40, 1.18)	0.92 (0.23, 3.71)	1.93 (1.09, 3.43)	0.91 (0.50, 1.66)	0.86 (0.57, 1.30)
Rosuvastatin	271 (13.7)	0.75 (0.52, 1.08)	1.01 (0.38, 2.73)	0.74 (0.40, 1.39)	0.73 (0.45, 1.16)	0.85 (0.63, 1.14)
Simvastatin	784 (39.5)	0.91 (0.74, 1.11)	0.66 (0.32, 1.34)	0.77 (0.53, 1.13)	0.90 (0.70, 1.17)	0.95 (0.80, 1.12)

HRs were determined via Cox proportional hazard models, adjusting for potential confounders including including geographic region, Charlson comorbidity index, a diagnosis of coronary artery disease, weight loss or anemia, pre-exposure use of aminosalicylates, 6MP or azathioprine, rectal steroids, outpatient contacts and hospitalizations prior to exposure. The adjustment set differed slightly for each outcome. Unexposed persons served as the referent group.

HR: Hazard ratio; NE: could not estimate (e.g. due to small cell size)